Mandarin Capital Triples Investment In Italian Pharma Co.

Law360, New York (February 27, 2012, 7:34 PM EST) -- Chinese private equity firm Mandarin Capital Partners has reportedly tripled its investment in a Milan-based pharmaceutical company after selling part of its majority stake to Italian firm Clessidra SGR SPA.

The deal, which breaks records for a China-based private equity firm, gives Clessidra a 30 percent share in Euticals SPA, a company now valued at $669 million, according to reports from U.K. news site The Alternative Assets Network.

Mandarin Capital, the world’s largest Sino-European private equity fund, retains a 24 percent stake in the company and...
To view the full article, register now.